Toward the development of vectored vaccines in compliance with evolutionary medicine

Expert Review of Vaccines

Volumn 7, Issue 4, 2008, Pages 399-402

  Tang, De Chu C ^a   Van Kampen, Kent R ^a  

^a Vaxin Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; ALUMINUM HYDROXIDE; ANTIBIOTIC AGENT; ANTIGEN; ESCHERICHIA COLI VACCINE; INFLUENZA VACCINE; LIVE VACCINE; ORAL POLIOMYELITIS VACCINE; TETANUS TOXIN; THIOMERSAL; VACCINE; VIRUS VECTOR;

ADENOVIRUS; ANTIGENICITY; AUTOIMMUNE DISEASE; CANCER RISK; CELLULAR IMMUNITY; DRUG CLEARANCE; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG SAFETY; EDITORIAL; ESCHERICHIA COLI; HEART DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; IMMUNIZATION; IMMUNOCOMPETENCE; INJECTION PAIN; MICROORGANISM; NEUROLOGIC DISEASE; PAIN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TETANUS; TISSUE INJURY; VACCINATION;

ANIMALS; BACTERIAL VACCINES; COMMUNICABLE DISEASES; GENETIC VECTORS; HUMANS; VIRAL VACCINES;

EID: 43249107518     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.4.399     Document Type: Editorial

References (24)

1. Poland GA, Jacobson RM. Understanding those who do not understand: a brief review of the anti-vaccine movement. Vaccine 19, 2440-2445 (2001).
2. Joseph A, Itskovitz-Cooper N, Samira S et al. A new intranasal influenza vaccine based on a novel polycationic lipid - ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice. Vaccine 24, 3990-4006 (2006).
3. Buge SL, Richardson E, Alipanah S et al. An adenovirus-simian immunodeficiency virus Env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J. Virol. 71, 8531-8541 (1997).
4. Wang J, Thorson L, Stokes RW et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J. Immunol. 173, 6357-6365 (2004).
5. Seder RA, Hill AV. Vaccines against intracellular infections requiring cellular immunity. Nature 406, 793-798 (2000).
6. Chen D, Erickson CA, Endres RL et al. Adjuvantation of epidermal powder immunization. Vaccine 19, 2908-2917 (2001).
7. Gherardi RK, Authier FJ. Aluminum inclusion macrophagic myofasciitis: a recently identified condition. Immunol. Allergy Clin. North Am. 23, 699-712 (2003).
8. Baker JP. Mercury, vaccines, and autism: one controversy, three histories. Am. J. Public Health 98, 244-253 (2008).
9. Eisenbraun MD, Fuller DH, Haynes JR. Examination of parameters affecting the elicitation of humoral immune responses by particle bombardment-mediated genetic immunization. DNA Cell Biol. 12, 791-797 (1993).
10. Shi Z, Zeng M, Yang G et al. Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines. J. Virol. 75, 11474-11482 (2001).
11. Van Kampen KR, Shi Z, Gao P et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23, 1029-1036 (2005).
12. Xiang ZQ, Yang Y, Wilson JM, Ertl HC. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology 219, 220-227 (1996).
13. Zhang J, Shi Z, Kong FK et al. Topical application of Escherichia coli-vectored vaccine as a simple method for eliciting protective immunity. Infect. Immun. 74, 3607-3617 (2006).
14. Tang DC, Shi Z, Curiel DT. Vaccination onto bare skin. Nature 388, 729-730 (1997).
15. Molinier-Frenkel V, Lengagne R, Gaden F et al. Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J. Virol. 76, 127-135 (2002).
16. Glenn GM, Scharton-Kersten T, Vassell R, Matyas GR, Alving CR. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect. Immun. 67, 1100-1106 (1999).
17. Couch RB. Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy. N. Engl. J. Med. 350, 860-861 (2004).
18. Hoelscher MA, Garg S, Bangari DS et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367, 475-481 (2006).
19. Lewis JA, Brown EL, Duncan PA. Approaches to the release of a master cell bank of PER.C6 cells; a novel cell substrate for the manufacture of human vaccines. Dev. Biol. (Basel) 123, 165-176 (2006).
20. Perkins S. Selection and optimization of anion exchange resins for purification of type 5 adenovirus. Presented at: Viral Vectors & Vaccines Conference, Southampton, Bermuda, 6-8 November, 2006.
21. Avakian AP, Poston RM, Kong FK, Van Kampen KR, Tang DC. Automated mass immunization of poultry: the prospect for nonreplicating human adenovirus-vectored in ovo vaccines. Expert Rev. Vaccines 6, 457-465 (2007).
22. Evans RK, Nawrocki DK, Isopi LA et al. Development of stable liquid formulations for adenovirus-based vaccines. J. Pharm. Sci. 93, 2458-2475 (2004).
23. Fallaux FJ, Bout A, van der Velde I et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum. Gene Ther. 9, 1909-1917 (1998).
24. Hilleman MR. Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. Vaccine 20, 3068-3087 (2002).